RecruitingNot applicableNCT03838445
Reducing Right Ventricular Failure in Pulmonary Arterial Hypertension (RELIEVE-PAH)
Studying Heritable pulmonary arterial hypertension
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- V-Wave Ltd
- Principal Investigator
- Victor Tapson, M.D.Cedars-Sinai Medical Center
- Intervention
- V-Wave Interatrial Shunt(device)
- Enrollment
- 20 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2020 – 2031
Study locations (5)
- Keck Medical Center of USC, Los Angeles, California, United States
- University of California, San Francisco, San Francisco, California, United States
- The Ohio State University Wexner Medical Center - Davis Heart & Lung Research Institute, Columbus, Ohio, United States
- Institut universitaire de cardiologie et de pneumologie de Québec - Université Laval, Québec, Canada
- Instituto Nacional de Cardiologia, Mexico City, Mexico
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03838445 on ClinicalTrials.govOther trials for Heritable pulmonary arterial hypertension
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT07498244Collagen Fingerprinting for Stratification of Pulmonary Hypertension (PH) PatientsMedical University of Graz
- RECRUITINGNANCT07079592A Deep-Learning-Enabled Electrocardiogram for Detecting Pulmonary HypertensionNational Defense Medical Center, Taiwan
- RECRUITINGPHASE4NCT07147114Clinical Trial to Evaluate the Efficacy and Safety in Concomitant Administration of Macitentan and Dapagliflozin in Patients With Heart Failure With Mildly Reduced and Preserved Ejection Fraction (HFmrEF and HFpEF) and Combined Pre- and Post-capillary Pulmonary Hypertension (CpcPH)Gachon University Gil Medical Center
- RECRUITINGPHASE2NCT07073820A Study to Learn About the Study Medicine (Called PF-07868489) in People With Pulmonary Arterial Hypertension Who Have Previously Participated in a Clinical Study With PF-07868489Pfizer
- RECRUITINGNCT07537517Evaluation of the BMPR2-Activin Signaling Pathway in Group II Pulmonary Hypertension.Hospital General Universitario Gregorio Marañon
- RECRUITINGNANCT07120789Validation of a Patient Knowledge Questionnaire for Pulmonary HypertensionUniversity of Sao Paulo General Hospital
- RECRUITINGNANCT07576894Right Ventricular Response to Exercise Among Patients With Chronic Obstructive Pulmonary DiseaseUniversity of Colorado, Denver
- RECRUITINGNCT07087613Deep Learning Detection of Pulmonary Hypertension and Low Ejection Fraction Via Digital Stethoscope and 3-Lead ECGEko Devices, Inc.
See all trials for Heritable pulmonary arterial hypertension →